Ther-Biotic Women's Formula
- Send to friend
- Customers Also Bought
- Customer feedback
Ther-Biotic Women's Formula 60 VCaps
Multispecies probiotic to support a woman’s genitourinary microflora health.
This high-potency hypoallergenic blend of nine certified probiotic species is specifically formulated to support the genitourinary system of girls and women of all ages by promoting a healthy vulvovaginal microbiota.
Ther-Biotic® Women’s Formula supplies substantial amounts of six specific Lactobacillus species and three Bifidobacterium species for their role in promoting dominance of normal indigenous vaginal microflora, restoring a healthy acidic vaginal pH, and supporting against colonization by harmful yeast and bacteria. Lactobacillus acidophilus and L. rhamnosus are included as these two probiotic species produce copious amounts of hydrogen peroxide that antagonize growth of pathogens and lactic acid to restore vaginal pH to a healthy range. Lactobacillus brevis, L. plantarum, L. salivarius and L. casei, all normally found in the vaginal microflora, also produce lactic acid to help create conditions for the re-emergence and dominance of normal indigenous lactobacilli. Bifidobacterium bifidum, B. longum, and B. breve are normal constituents of the vaginal microbiota, resist colonization of the vagina by pathogens such as Escherichia coli and Candida, and promote growth of indigenous healthy lactobacilli.
For me, one of the most welcome movements in clinical nutrition has been the focus placed on patient outcome where satisfaction is becoming more important in determining clinical success than our agendas or lab results. We are now beginning to realize that, as supplement suppliers, when we listen to the patient's concerns, we may need to go beyond that of detox, gut, and adrenal function. One area of patient care that I feel has not received proper focus in our agenda-based manufacturing environment is genitourinary health in women. Therefore, I was quite excited to learn that Klaire Labs, a leader in the production of probiotic supplements, has released Ther-Biotic Women's Formula in both powder and capsule form.
Why is this product so special and timely? First, consider the extent of the problem. In his paper "Vulvovaginal candidosis," Sobel (Sobel JD, Lancet, Vol. 369, pp. 1961-1971, June 9, 2007) discusses the staggering prevalence of just this one aspect of genitourinary dysfunction in women:
"The infection-caused by Candida spp-affects 70-75% of women at least once during their lives, most frequently young women of childbearing age. 40-50% of women will experience a recurrence. 5-8% of adult women have recurrent vulvovaginal candidosis, defined as four or more episodes every year. In one study, almost 30% of the women with symptoms of vulvovaginitis had yeast isolated, confirming the diagnosis of vulvovaginal candidosis. Other authors indicate that vulvovaginal candidosis is responsible for 15-30% of vulvovaginal symptoms."
As you might expect, many papers have documented that direct vaginal implantation of probiotic organisms has demonstrated a very positive impact. However, given the patient compliance issues inherent with such a method of delivery, you may have wondered if oral administration of probiotic organisms could also have a favorable impact.
Interestingly, I located two studies which did report positive findings with oral administration.
Both studies were authored by Reid et al. In "Oral probiotics can resolve urogenital infections" (FEMS Immunol Med Microbiol, Vol. 30, pp. 49-52, 2001) the authors begin by emphasizing prevalence of the problem, particularly the in relation to increased drug resistance:
"Urogenital infections, including urinary tract infections (UTI), bacterial vaginosis (BV) and yeast vaginitis, afflict an estimated 1,000,000,000 people in the world annually. For patients suffering from BV, they have an increased risk of preterm labor and acquisition of sexually transmitted disease. While antimicrobial agents are quite effective at providing clinical cure for bacterial infections, urogenital pathogen drug resistance is on the increase..."
In their study Reid et al administered two lactobacillus species orally to 10 women who had a recent history of urogenital infection daily for 14 days. The results of this study were the following:
- "The results showed that L. rhamnosus GR-1 and/or L. fermentum RC-14 were recovered from the vagina within one week in all 10 patients."
- What about clinical outcome?
- "No side effects were noted. All patients reported improved well being with therapy. This included relief of symptoms of urogenital infection, and reportedly no need for monthly yeast therapy."
- Reid et al go on to discuss the significance of their findings:
- "This study is significant for a number of reasons. Unlike antibiotic therapy used to prevent recurrence of UTI, there were no side effects and patients reported improved welling and relief from their monthly cyclical recurrences of yeast vaginitis, BV or UTI."
- The authors continue:
- "The critical finding was the first conclusive proof that two probiotic lactobacilli, specifically selected for their ability to inhibit urogenital pathogen growth and adhesion, can colonize the vagina following oral intake. Notably, in each patient, one or both of the strains colonized the vagina, and remained several months thereafter."
"This means that the organisms successfully survived the low pH and bile salt of the stomach, and passage through the intestine, and that they then ascended without functional intervention, into the vagina."
In the second study, "Probiotic lactobacillus dose required to restore and maintain a normal vaginal flora" (FEMS Immunol Med Microbiol, Vol. 32, pp. 37-41, 2001), Reid et al attempted to determine optimal oral dosing of probiotics required to restore normal vaginal flora. In this experiment the same organisms as used in the first study were administered twice daily for six weeks to 42 women. All were 17 years of age and over and had a history of urogenital infections but were currently free from infection. The women were divided into several groups, each receiving different daily dosages.
What were the results? While all the women, regardless of dose, demonstrated significant levels of the test organisms in the vagina, the following criteria was suggested concerning optimal dose:
"...a daily dose greater than 8 x 108 is required for an effect."
Ther-Biotic Women's Formula 60 VCaps | Klaire Labs
Dosage Form: Vegetarian Capsule
Each serving (1 capsule) contains:
- Probiotic Blend (25+ billion CFUs) 155 mg*
- Lactobacillus species 20+ billion CFUs*
- Lactobacillus acidophilus
- Lactobacillus brevis
- Lactobacillus salivarius
- Lactobacillus casei
- Lactobacillus rhamnosus
- Lactobacillus plantarum
- Bifidobacterium species 5+ billion CFUs*
- Bifidobacterium breve
- Bifidobacterium bifidum
- Bifidobacterium longum
Other Ingredients: Inulin base derived from chicory root, vegetarian capsule (hydroxypropyl methylcellulose, water), InTactic® proprietary polysaccharide complex, and L-leucine.
*Your results may vary.
Your results may vary from those listed above.
These statements have not been evaluated by the Food and Drug Administration.
This product is not intended to diagnose, treat, cure or prevent any disease.
Since we do not know everything about your medical history and medications, please consult with your health care practitioner before implementing any new protocols and supplements. Do not construe any information listed on this site as a substitute for actual medical advice. The info you receive from us is not intended to replace medical advice by your doctor. Forrest Health, Inc. does not dispense medical advice, prescribe, or diagnose illness. We offer nutritional programs and supplements that support your health. The views and nutritional advice expressed by Forrest Health, Inc. are not intended to be a substitute for conventional medical service. If you have a medical condition, see your physician of choice